P21 vs Palmitoyl Tripeptide-1
A detailed comparison to help you understand the differences and choose the right peptide for your research goals.
P21
P21 is a synthetic peptide derived from Cerebrolysin, specifically designed to mimic the neurotrophic effects of the parent compound. It promotes neurogenesis and has shown cognitive-enhancing properties in research.
Full details →Palmitoyl Tripeptide-1
Palmitoyl Tripeptide-1 (Pal-GHK) is a lipopeptide that stimulates collagen production. It's one of two peptides in the Matrixyl 3000 complex, working synergistically with Palmitoyl Tetrapeptide-7.
Full details →Side-by-Side Comparison
| Aspect | P21 | Palmitoyl Tripeptide-1 |
|---|---|---|
| Mechanism | Inhibits glycogen synthase kinase-3β (GSK-3β) and activates CREB signaling pathway. This promotes BDNF expression, neurogenesis in the hippocampus, and synaptic plasticity. | Mimics the skin's own mechanism for producing collagen by acting as a messenger peptide that signals fibroblasts to produce more collagen and other extracellular matrix components. |
| Typical Dosage | Research protocols typically use 1-5mg administered intranasally or subcutaneously. Often used in cycles of 2-4 weeks. | Topical: Typically 2-4% in serums, often combined with Palmitoyl Tetrapeptide-7 as Matrixyl 3000. |
| Administration | Can be administered intranasally for direct CNS access or subcutaneously. Best used cyclically rather than continuously. | Topical application 1-2 times daily. The palmitoyl group enhances skin penetration compared to non-lipidated versions. |
| Side Effects | Limited data. Reported effects include mild headache, temporary brain fog during initial use, and fatigue. | Very well-tolerated. Suitable for most skin types including sensitive skin. |
| Best For |